Table 3.
Total† | No (%) of women with postpartum hemorrhage | Covariates in propensity score model | |||
---|---|---|---|---|---|
Delivery year | Investigator defined‡ | Investigator defined‡ and empirically defined | |||
SRI monotherapy | 10 203 | 415 (4.1) | 1.46 (1.32 to 1.61) | 1.47 (1.32 to 1.64) | 1.52 (1.35 to 1.71) |
Unexposed | 53 348 | 1479 (2.8) | Reference | Reference | Reference |
Non-SRI monotherapy | 1162 | 45 (3.9) | 1.39 (1.06 to 1.82) | 1.49 (1.12 to 1.98) | 1.39 (1.03 to 1.89) |
Unexposed | 52192 | 1475 (2.8) | Reference | Reference | Reference |
SRI=serotonin reuptake inhibitor.
*Women with highest and lowest 2.5% of propensity score excluded from analyses.
†Numbers are for trimmed population in investigator defined and empirically defined covariates analysis.
‡Investigator defined covariates: delivery year, age, race, multiple pregnancy, diabetes, coagulopathy, number of outpatient mood/anxiety disorder diagnoses, number of inpatient mood/anxiety disorder diagnoses, psychotic disorder, other mental health disorder, pain indication, sleep disorder, anticonvulsant dispensing, benzodiazepine dispensing, aspirin dispensing, heparin dispensing, low molecular weight heparin dispensing, and number of outpatient visits and days in hospital during baseline.